Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 8, Issue 11, Pages 1723-1731Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.8.11.1723
Keywords
metastatic; platelet-derived growth factor; renal cell carinoma; sunitinib; vascular endothelial growth factor
Categories
Funding
- Pfizer Inc
Ask authors/readers for more resources
Kidney cancer accounts for approximately 2% of new cancers and conventional treatment with nephrectomy followed by IL-2 or IFN-alpha treatment does not provide long-term survival benefit in many patients. Increased understanding of the pathophysiology of renal cell carcinoma has prompted the development of targeted therapies for patients with this disease, including sunitinib. This paper reviews the most recent efficacy and safety data for sunitinib, as well as currently ongoing and planned studies for this receptor tyrosine kinase inhibitor. Results from a large-scale, long-term, Phase III trial have established sunitinib as the standard of care for first-line treatment of patients with advanced renal cell carcinoma, and it is now the reference standard against which other therapies for this cancer should be evaluated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available